Atlas Trials

Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion

Clinical trial NCT02044822 · TERMINATED

Trial details

NCT number
NCT02044822
Sponsor
Gilead Sciences
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
B-cell Chronic Lymphocytic Leukemia (CLL) With 17p Deletion
Start date
2014-08-06
Primary completion
2016-04-27
Enrollment
102

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.